OCC 2.78% 35.0¢ orthocell limited

J&J Partnership, page-306

  1. 7,514 Posts.
    lightbulb Created with Sketch. 6768
    Little reminder gents (and ladies) of the trial:

    https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372643

    Secondary outcomes are function and pain measurements including VAS scores. Lets not forget on a 0-10 pain score, ATI saw improvements from 5.94 at the initial assessment to 0.76 at 12 months (P < .001) in its lateral epicondylitis study. The best measure of the success was for me grip strength scores improving over the 12-month follow-up from 20.17 kg [baseline] to 37.38 kg; P < .001):

    https://journals.sagepub.com/doi/abs/10.1177/0363546513504285

    Pretty compelling stuff for those who've ever endured tendinosis. I am very excited by these forthcoming results and only wish they'd including more secondary data - but too many studies get loaded down with multiplicity criticisms, so OCC have kept it simple with preferred orthcopedic composite measures.
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
(20min delay)
Last
35.0¢
Change
-0.010(2.78%)
Mkt cap ! $73.26M
Open High Low Value Volume
36.0¢ 36.0¢ 35.0¢ $82.13K 232.2K

Buyers (Bids)

No. Vol. Price($)
7 92207 35.0¢
 

Sellers (Offers)

Price($) Vol. No.
35.5¢ 27779 1
View Market Depth
Last trade - 16.10pm 08/07/2024 (20 minute delay) ?
OCC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.